Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
4.000
+0.290 (7.82%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.

It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.

It has a collaboration with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.

Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc.
Cabaletta Bio logo
Country United States
Founded 2017
IPO Date Oct 25, 2019
Industry Biotechnology
Sector Healthcare
Employees 103
CEO Steven Nichtberger

Contact Details

Address:
2929 Arch Street, Suite 600
Philadelphia, Pennsylvania 19104
United States
Phone 267 759 3100
Website cabalettabio.com

Stock Details

Ticker Symbol CABA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $11.00
CIK Code 0001759138
CUSIP Number 12674W109
ISIN Number US12674W1099
SIC Code 2836

Key Executives

Name Position
Dr. Steven A. Nichtberger M.D. Co-Founder, Chairman, Chief Executive Officer and President
Dr. David J. Chang FACR, M.D., M.P.H. Chief Medical Officer
Dr. Gwendolyn K. Binder Ph.D. President of Science and Technology
Dr. Michael C. Milone M.D., Ph.D. Co-Founder and Co-Chair of Scientific Advisory Board
Dr. Aimee Payne M.D., Ph.D. Co-Founder and Co-Chair of Scientific Advisory Board
Anup Marda M.B.A. Chief Financial Officer
Dr. Qing Sarah Yuan Ph.D. Chief Technology Officer
Dr. Samik Basu M.D. Chief Scientific Officer
Michael Gerard J.D. General Counsel and Secretary
Heather Harte-Hall M.Sc. Chief Compliance Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 17, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 7, 2024 8-K Current Report
Sep 30, 2024 8-K Current Report
Aug 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jun 14, 2024 8-K Current Report